semustine
Small moleculeexperimental
Semustine is an alkylating nitrosourea compound used in chemotherapy treatment of various types of tumours. Due to its lipophilic property, semustine can cross the blood-brain barrier for the chemotherapy of brain tumours, where it interferes with DNA replication in the rapidly-dividing tumour cells. Semustine, just as lomustine, is administered orally. Evidence has been found that treatment with semustine can cause acute leukaemia as a delayed effect in very rare cases. — Wikipedia
Clinical trial activity
9 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
6
Phase 3
7
Phase 4
0
Earliest trial started Sep 1, 1977 (NCT00427570)
Timeline
Indications
Studied for
- Astrocytoma · Phase 3
- Colorectal Neoplasms · Phase 3
- Glioblastoma · Phase 3
- Graft vs Host Disease · Phase 3
- Hematopoietic Stem Cell Transplantation · Phase 2/Phase 3
- Leukemia · Phase 3
- Leukemia, Myeloid, Acute · Phase 2/Phase 3
- Lymphoma, T-Cell, Peripheral · Phase 3
- Recurrence · Phase 3
- Vascular Grafting · Phase 3
Mechanism of action
- DNACROSS-LINKING AGENT
DNA cross-linking agent
Chemistry & pharmacology
Loading structure…
SMILES
CC1CCC(NC(=O)N(CCCl)N=O)CC1- Mol. weight
- 247.73 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSemustine ↗
- ChEMBLCHEMBL12948 ↗
Also known as
- methyl-ccnu
- methyl-ccnu
- methyl-ccnu
- methyl lomustine
- semustine
- semustine
- semustine
- semustine
- semustine
- semustine
- semustine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05814731 | N/A | Apr 15, 2023 | Jiao Tong University |
| NCT04945096 | Phase 3 | Jul 1, 2021 | Soochow University |
| NCT04688021 | Phase 2 | Dec 3, 2020 | Zhejiang University |
| NCT04880746 | Phase 3 | Oct 17, 2020 | Anhui Medical University, Dalian Medical University, Fudan University, Fujian Medical University, Harbin Medical University, Jiao Tong University, People's Liberation Army of China, Shandong University, Shanxi Medical University |
| NCT04547049 | Phase 3 | Sep 1, 2020 | Zhejiang University |
| NCT03799224 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2018 | Peking University |
| NCT03793517 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2018 | Peking University |
| NCT00335075 | Phase 3 | Mar 2, 2005 | Merck |
| NCT00427570 | Phase 3 | Sep 1, 1977 | Allegheny Health Network, National Cancer Institute (NCI), NSABP Foundation |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiao Tong University | Academic/Hospital | 2 | 2 | 2 | 2020 |
| Peking University | Academic/Hospital | 2 | 2 | 1 | 2018 |
| Zhejiang University | Academic/Hospital | 2 | 2 | 2 | 2020 |
| Allegheny Health Network | Academic/Hospital | 1 | 0 | 1 | 1977 |
| Anhui Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Dalian Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Fujian Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Harbin Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Merck | For profit | 1 | 1 | 1 | 2005 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1977 |
| NSABP Foundation | Academic/Hospital | 1 | 1 | 1 | 1977 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2020 |
| Shandong University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Shanxi Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Soochow University | Academic/Hospital | 1 | 1 | 1 | 2021 |
16 organizations
Page 1 / 1